Form 4: Verona Pharma CMO Gifts Shares Under 10b5-1 Plan

Verona Pharma's Chief Medical Officer, Kathleen A. Rickard, reported gifting 189,600 ordinary shares under a pre-arranged plan.

Summary

• Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc, reported a disposition of 189,600 Ordinary Shares.
• The transaction occurred on August 29, 2025, and was a gift (transaction code 'G') with a price of $0 per share.
• Following this transaction, Ms. Rickard beneficially owns 2,417,872 Ordinary Shares.
• These shares consist of 647,480 Ordinary Shares underlying Restricted Share Units (representing 80,935 ADSs) and 1,770,392 Ordinary Shares underlying 221,299 ADSs.
• Each American Depositary Share (ADS) of Verona Pharma plc represents eight Ordinary Shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled event.

Sentiment

Score: 5

Explanation: The filing reports a gift of shares by a Chief Medical Officer, which is a routine insider transaction. While it reduces direct ownership, it is not a sale and the insider retains substantial holdings, making the overall sentiment neutral.

Negatives

• The disposition of 189,600 Ordinary Shares by a key executive, even as a gift, reduces their direct equity stake in the company. This could be perceived by some investors as a slight reduction in the executive's direct financial alignment with shareholders, although the overall beneficial ownership remains substantial.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The direct equity alignment of a key executive with shareholders is slightly reduced due to the gift, though the executive retains significant beneficial ownership.

Key Dates

Recommendation

The filing reports a routine insider transaction (a gift of shares) by a Chief Medical Officer. This event alone does not provide sufficient new information to alter an investment thesis for Verona Pharma plc, as the insider retains substantial beneficial ownership. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis.

Keywords

Verona Pharma, VRNA, Form 4, Insider Transaction, Share Gift, Chief Medical Officer, Kathleen A. Rickard, Ordinary Shares, ADSs, Restricted Share Units, 10b5-1 Plan